Member Info for inanaco

https://www.bbc.co.uk/iplayer/episode/b03wyr3c/horizon-20132014-9-how-you-really-make-decisions

fascinating ..

apply that to the SP ... !!

one off payments are rare ... up front, staged payment relative to results are common ..

Not trying to convince ,,,,, just make you think on your structure of the post .. by highlighting .. indeed it worked NDA has appeared

so BioNtech are going to announce a deal not signed before they float ? to raise cash to pay for the deal .. ?

really ?

Big Difference Knowlesi this is the first fund raise that has not been just directed at utilizing tax breaks for funding ..

this is a serious Bio investment with the Main Man sitting on the Board with the full long term backing of the specialist fund which is a huge seal of approval from existing holders and new that track the investments made by these fund managers as they do the ground work prior to making the investment .

SO CRUK has completed due diligence and is now preparing for manufacture and a trial

and now serious Bio Money men and stepping up to invest ...

what is not to like ?

TCR is a very serious investment which has been galvanized by many Car T trials which need help in solid cancers the industry has made serious investments in this area especially as they can clone out a data base of TCR's from patients neo antigens. BioNtech is advertising that its in this area, i would suggest they would want to show potential stockmarkets that they do have a potential TCR program against ALL the major solid cancers potentially using MOD1/2/3 epitopes plus others still to be defined. As i have pointed out before its potentially a Billion plus investment across the spectrum ... and if you are going to present a program for the Float leaving Moditope out is not sensible marketing ....just because of the Scale of its expansion

Boris 114

scancell up 32.71

Of this week issue of the Trader ....

https://www.designcrowd.com/design/12865761

Knowlesi and the smoking gun ... dam missed

if you look at the 10 year average i bet its around 20p ...

what drove the share to 60p is now about to enter trial in 6 months .......... why would you think it would pull back

we have 3 major trials starting over the next 18 months

scib1 and 2

Modi1

Gets the Science sufficient to commit long term funding and get a place on the BOD ... what confidence he has in the Science ....

we kept our cool and kept plugging the science ....

Game on

our sp average is in the 20's not in single figures ....

Moditope is coming !!

first patient treated with keytruda is near

Exhaustive research into TCR continues a pace ......... Genetech (Roche) recent buy suggest legs

Karolinska has something .... !!! to be announced

Homocitrulline patent a companion vaccine to citrullinated and even more potent that it will attack cold cancers

we have a Glycan Platform ... killer Antibodies ...

we have Immunopbody proven in trial ....

CRUK aboard

all areas turn scancell into a cash register with all area developed in house ...

Confidence

Stephen and Martin Diggle with Martin as a NED

has give the Green light to Buy ....

1/ they have money
2/ This is what they do
3/ they have BOD level representation
4/ they have not just jumped in blind

tick tock

all about the science

You are desperate .... its shows

its never been about City Financial or Knowlesi or any other "flaw"

the reason why pessimists will not win this one is because Optimists run Scancell ... and the PHD Lindy ... "the Inventor"

of a "cure for cancer"

we have patients "clear "

and if Moditope takes off ....... scancell becomes a cash register

we trust in you Ruck ... how is your VAL risk management going ....

and Knowlesi was after a cheap Buy .. as i predicted at the time he missed his entry point at 3.6p would you like a reprint ?

Major fund behind us .. supportive at Board Level ....

whats not to like ?

Tick Tock

anyway back to the real world ...

did any post i made today support MM codes

so Knowlesi why suggest i did >

standing here as a swiss time piece ... ... in my cuckoo land ..

1. Retired ... your not
2. Happy with the SP .... your not .... as i bought at 3.9p

not sure why Holding like you is abhorrent ...

or is it the size of that holding ?

Knowlesi is in a Quantum field ..

He is "Holding" and moaning about the share, while holding a bazooka cash pile to buy on weakness which justify's his moaning about the share ....

in reality ... the SP is getting stronger ... and an RNS is due "First person treated with SCIB1 and Keytruda "

agree with you Roses . looks like they have sold 401 at a loss

PD1 shows up everywhere in the immune system ... which is why Keytruda and checkpoints have toxicity ..

take vascular decease ............

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6457250/

PD-1 is exclusively expressed on activated immune cells, most importantly on T cells, thus exclusively regulating ongoing immune responses, both in secondary lymphoid organs and in peripheral tissue sites. Engagement of PD-1 by its ligand PD-L1 (B7-H1, CD274) downregulates TCR and CD28-mediated activation cascades. PD-1 inhibits signaling pathways involved in glucose metabolism and cell cycle regulation, including the PI3K–Akt–mTOR and Ras–MEK–ERK pathways, thus impacting critical survival functions in normal tissues [16–18]. PD-L1 is expressed on antigen-presenting cells (dendritic cells, macrophages etc) and on endothelial cells (EC). In animal studies, the PD-1 immune checkpoint has been implicated in protecting tissue tolerance and disruption of PD-1 and PD-L1-associated negative signaling has been associated with inflammatory disease [19–21]. Remarkably, PD-L1 is often abundantly expressed in cancer cells, and has been implicated in the immune evasion strategy of malignant cells, that paralyze anti-tumor T cells by engaging their PD-1 receptors. Accordingly, therapeutic blockade of PD-1 or PD-L1 in cancer patients has heralded in a revolution in cancer immunotherapy.